Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
PepsiCo's North America Segment Remains Work in Progress, Deutsche Bank Says

PepsiCo's North America Segment Remains Work in Progress, Deutsche Bank Says

MT newswireMT newswire2026/10/09 17:10

01:10 PM EDT, 10/09/2026 (MT Newswires) -- PepsiCo's (PEP) North America segment remains a work in progress, even as the company continued to enjoy resilient momentum in its International business, Deutsche Bank said in a Friday note. Initiatives like affordability investments, evolved advertising, brand restaging, among others, have made little improvement in unit volume for PepsiCo Foods North America, while PepsiCo Beverages North America remains a "laggard competitively with weak margins," the bank said. While the company's management has discussed a number of prospective and ongoing actions that aim to improve near-term performance, it offered less clarity on how such actions will collectively lead to a "credibly improved growth and earnings algorithm by fiscal 2028," Deutsche Bank added. The bank has a hold rating and $132 price target on the company. Price: 126.40, Change: -1.95, Percent Change: -1.52

01:10 PM EDT, 10/09/2026 (MT Newswires) -- PepsiCo's (PEP) North America segment remains a work in progress, even as the company continued to enjoy resilient momentum in its International business, Deutsche Bank said in a Friday note. Initiatives like affordability investments, evolved advertising, brand restaging, among others, have made little improvement in unit volume for PepsiCo Foods North America, while PepsiCo Beverages North America remains a "laggard competitively with weak margins," the bank said. While the company's management has discussed a number of prospective and ongoing actions that aim to improve near-term performance, it offered less clarity on how such actions will collectively lead to a "credibly improved growth and earnings algorithm by fiscal 2028," Deutsche Bank added. The bank has a hold rating and $132 price target on the company. Price: 126.40, Change: -1.95, Percent Change: -1.52
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21